Robert Laugherty,

JD, MBA, PA-C

Robert Laugherty,

JD, MBA, PA-C
Physician Assistant and Director of Rheumatology, East Tennessee Medical Group

Robert Laugherty,

JD, MBA, PA-C
Physician Assistant and Director of Rheumatology, East Tennessee Medical Group
Robert Laugherty, JD, MBA, PA-C, is the director of rheumatology at East Tennessee Medical Group in Alcoa, Tennessee. He earned a bachelor’s degree in journalism from the University of Florida, his juris doctor degree and master of business administration degree from the University of Tennessee, and physician assistant degree from the Medical College of Georgia in 2000. He discovered that rheumatology was his calling after time spent in emergency medicine and internal medicine and has been in the specialty for almost two decades. He is a founding member of Rheumatology Advance Practice Providers, a society devoted to the education and training of physical associates and nurse practitioners in rheumatology practice.

Robert's Shared Resources

CASPAR Criteria Outperform Legacy Tools in Identifying Psoriatic Arthritis

Psoriatic arthritis (PsA) is a systemic, chronic inflammatory arthritis commonly associated with psoriasis and typically seronegative for rheumatoid factor....
Robert Laugherty,
CURATED BY:
Robert Laugherty,
JD, MBA, PA-C

GRAPPA Consensus on Comprehensive Treatment Recommendations for Psoriatic Arthritis

The objective of this study was to develop comprehensive treatment recommendations for the various clinical manifestations of psoriatic arthritis (PsA),...
Robert Laugherty,
CURATED BY:
Robert Laugherty,
JD, MBA, PA-C

Evaluating the Clinical, Economic, and Humanistic Burden of Psoriatic Arthritis

This literature evaluated the clinical, economic, and humanistic burden of psoriatic arthritis (PsA). The review focused on studies published between...
Robert Laugherty,
CURATED BY:
Robert Laugherty,
JD, MBA, PA-C

Understanding Psoriatic Arthritis: IL-17’s Role and Promising Targeted Therapies

Psoriatic arthritis (PsA) is a chronic inflammatory condition that typically follows psoriasis (PsO), with skin involvement often preceding joint issues,...
Robert Laugherty,
CURATED BY:
Robert Laugherty,
JD, MBA, PA-C

Long-Term Efficacy of TNF Inhibitors in PsA

This observational study evaluated the long-term clinical outcomes of adalimumab (ADA), etanercept (ETN), and infliximab (IFX) in biologic-naive patients with...
Robert Laugherty,
CURATED BY:
Robert Laugherty,
JD, MBA, PA-C

Targeting PDE4 for Effective Treatment of PsA

Phosphodiesterases (PDEs) are enzymes that degrade the second messengers cAMP and cGMP, influencing processes like cell proliferation, apoptosis, inflammation, and...
Robert Laugherty,
CURATED BY:
Robert Laugherty,
JD, MBA, PA-C
Share